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Purpose or Objective 
In IMRT any point at the patient’s skin can be at the same 
time the entrance for some beam angles and the exit for 
others. Pure entrance correction factors (CFentrance) for skin 
in vivo dosimetry do not apply if some beams exit through 
the detector surface or in case of a mixed entrance-exit 
scenario. This study was aimed to establish a method to 
perform reliable skin in vivo dosimetry for IMRT 
techniques. 
Material and Methods 
Ultra-thin TLDs with an effective point of measurement 
(EPOM) at a depth < 5 mg/cm2 and EBT3 radiochromic films 
(RCF) with EPOM~120 mg/cm2 were compared against the 
results of a PTW23392 Extrapolation Chamber (EC) with an 
entrance window ~0.7 mg/cm.2 TLD and RCF were 
enclosed inside sleeves of LowDensityPolyEthylene (LDPE) 
to allow placing them in contact to patient skin. CFentrance 
for TLD and RCF were derived by comparing measured 
doses with the detectors against those measured with the 
EC. Devic et al showed that RCF correction factors for exit 
dose measurements CFexit=1. This value was also applied 
to ultrathin TLDs when enclosed in LDPE, as their sensitive 
layer laid at a water equivalent depth of 70 μm. A 
cumulative correction factor (CF*) was proposed for 
integrated dose measurements using 6 MV photon beams 
as a linear combination of CFentrance and CFexit. The 
combination coefficients were 1-PDD and PDD being PDD 
the depth dose for the average field size at the depth of 
the average phantom thickness for all beams. CF* was 
tested with two phantom experiments: 
1-Irradiation by two opposed fields of a Plastic Water slab 
phantom of 30X30 cm2. Three different thickness (10,15 
and 20cm) of the phantom were considered. 
Measurements with only the entrance field and with both 
fields allowed us to know the delivered skin doses and 
compare them with those predicted by the model. 
2-Delivery of a breast IMRT treatment plan on a QUASAR 
phantom. We compared the measurements of TLD and RCF 
in 8 consecutive points along the central axis at 2.5 cm 
distance one another. 
Results 
Table 1 shows cumulative skin doses derived from 
measurements, Dskin,cumulative, and those calculated by the 
model (Dskin,cumulative*) as a function of the slab phantom 
thickness for 6MV photon beams. Differences between the 
skin doses derived from TLD measurements and those 
derived from RCF measurements were between 0 and 10%, 
with a RMS=5%. The RMS of the differences between the 
values derived from measurements and those calculated 




Table 2 shows skin doses measured with TLD and RCF in 
eight points of the QUASAR phantom after delivering an 
IMRT treatment plan. Raw doses measured with TLDs and 
with EBT3 RCF, and corrected skin cumulative doses for 
EBT3 RCF are shown. The application of the proposed 
cumulative correction factor CF* improved the Root Mean 
Square (RMS) of the differences between TLD 





The proposed CF* enables us to perform integrated skin 
dose measurements for IMRT with the lowest uncertainty 
reported to date. 
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Purpose or Objective 
Total skin electron therapy (TSET, sometimes called TSEI 
or TSEBT) is delivered to patients who are standing in a 
series of well-established poses, rather than lying on a 
treatment couch. This unusual treatment geometry means 
that the dose received by each patient needs to be 
calculated without the use of a planning CT and usually 
without the use of a computerised treatment planning 
system. The treatment dose must therefore be verified, 
monitored and potentially adjusted throughout the 
treatment course, using in vivo dosimetry measurements. 
The aim of this study was to retrospectively examine a set 
of in vivo optically stimulated luminescence dosimetry 
(OSLD) measurements, and thereby provide an indication 
of the value of OSLD measurements for establishing and 
improving the dosimetric accuracy of TSET treatments, as 
well as proposed guidelines for completing such 
measurements in future. 
Material and Methods 
Treatment records, including in vivo OSLD measurement 
data, were obtained for the ten patients who received 
TSET treatments during the last five years, at one large, 
metropolitan radiotherapy facility. Prescription doses 
ranged from 12 to 32.5 Gy, over 6 to 15 treatment cycles. 
Between 4 and 40 OSLD measurement points were used for 
each patient, at each cycle, depending on the number of 
areas of dosimetric concern identified by the prescribing 
oncologist or the physics team. All OSLDs were Landauer 
nanoDots, which were read out using a microStar reader 
(Landauer Inc, Glenwood, USA). 
Results 
The in vivo dose measurements resulted in MU 
adjustments in five of the ten cases, to compensate for 
dose differences of 3.5% to 16% that resulted from changes 
in patient stance between treatment planning and 
delivery. Doses measured on the chest, back and around 
the waist were relatively consistent (see figure 1), under-
doses were frequently identified at the top of the head, 
around the thighs and groin and in the armpits (see figure 
2), and over-doses requiring the use of additional shielding 
were occasionally identified at extremities. 







OSLDs can be used to obtain measurements of TSET dose 
with sufficient accuracy to justify treatment dose 
adjustments and indicate the need for additional shielding 
or boost treatments. The identification and consistent use 
of a specific set of measurement points would increase the 
value of future in vivo measurement data, as a local audit 
and quality improvement resource. 
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Purpose or Objective 
The new fully pre-configured system dedicated for the fast 
delivery of IMRT/VMAT, Varian Halcyon™, a 6MV-FFF linac 
mounted on an O-ring gantry was installed in our centers. 
The Anisotropic Analytical Algorithm v15.6 (AAA) has been 
pre-configured to allow the calculation of patient 
dosimetry. It is also used to predict the dose in EPID for 
patient pre-treatment quality assurance (QA) with IMRT 
technique. With this one it is not possible to customize the 
beam modeling.  
The purpose is to validate the Varian Portal Dosimetry 
(VPD) system against the standard QA system (diode array 
2D), in order to use it for routine QA. 
Material and Methods 
Dosimetric data were collected using the linac Varian 
Halcyon 2.0 with the 2D diode matrix Sun Nuclear 
MapCHECK2™ and the VPD with the AAA algorithm. 
Treatment Planning System (TPS) Eclipse™ version 
15.6  was used to generate 26 alphabetical letters (A to Z) 
with the fluence brush tool (for example graph below for 
the letter h), 7 sweeping gaps (2, 4, 6, 10, 14, 16, 20mm) 
and 10 breasts cancers treatment with IMRT technique. 
The measured fluences with MapCHECK2™ were analyzed 
versus TPS dose water matrices (AAA V15.6) with the SNC 
software (V6.7.8) and predicted fluences with VPD (AAA 
V15.6). 
Results 
For alphabetical letters and sweeps gaps, the mean 
passing rates of the global gamma evaluation were 
99.04±2.47% and 88.10±5.37% and the local gamma 
evaluation were 98.82±2.47% and 86.98±5.13%, for the 
2%/2 mm and 1%/1 mm criteria, respectively, for 
MapCheck2.  
In the case of the portal dosimetry, the mean passing rates 
of the gamma evaluation were 99.18±3.73% and 90.75± 
8.77% and the local gamma evaluation were 99.15±3.75% 
and 89.72± 8.77%  for the 2%/2 mm and 1%/1 mm criteria 
respectively. 
For breast IMRT treatments, the mean passing rates of 
local gamma evaluation were 99.9±0.28% and 99.9±1.68% 
for VPD and 99.56±0.65% and 97.49±1.86% for MapCheck2 





The pre-configured portal dosimetry beam modeling gives 
a very good results and close to the 2D array detector. It 
seems enough robust to use for routine QA without any 
need to customize. 
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Purpose or Objective 
Implementation of Lung SBRT in clinical routine requires 
an extensive quality control program to assure patient 
safety. Patient-specific evaluation of the measured dose 
against the treatment planning calculated dose is essential 
in this context.  While several commercial 3-D detector 
arrays are available, they do not provide alone sufficient 
information to analyze complex dose distribution of highly 
conformal radiotherapy. Given the high resolution of 
Gafchromic films, we developed a proof of concept for a 
pre-treatment QA procedure using EBT3 films placed 
inside the body of a commercial X-shaped 3-D detector 
arrays phantom. 
Material and Methods 
The Delta4 phantom has been modified by replacing the 
three detector plates (main board and wings) by EBT3 film 
placed in between 5mm thick PMMA slabs (Figure 1). Dose 
distribution of a three-arc VMAT (RayStation Version 6.0) 
plan for Lung SBRT (fraction dose of 15Gy, 6MV) was 
calculated on the homogeneous cylindrical body of the 
phantom and delivered using Elekta Synergy machine with 
Agility head. Calculated dose in the film planes (main 
plane 50° to the sagittal plane) was exported via a home-
made script and compared to the measured film dose using 
FilmQAPro software (Ashland ISP, USA) three-channel 
dosimetry. All specific film handling precautions were 
followed [1,2]. For quantitative evaluation, the gamma 




index metric with 2%/2mm and 3%/3mm criteria was used 
in Film QA pro. 
Results 
Relative and absolute dose comparison was performed 
with 2%/2mm gamma analysis of 92, 85 and 86% for the 
main and the wing films respectively; increasing up to 98, 
93 and 96% using conventional 3%/3mm criterion. Results 
are presented in Figure 2 with vertical and horizontal line 
profiles couple to an isodose map of the main film. Having 
high resolution data into two perpendicular planes in a 
cylindrical phantom is advantageous against the classical 
setup in a cubic slab phantom. It provides more 
information than a single film in a coronal plane and 
reflects a geometry closer to the anatomical region 




Figure 1. Adapted Delta4 phantom with film slabs. Left: 




Figure 2. Film versus planned (solid line) isodose map and 
perpendicular dose profiles in the main plane 
Conclusion 
Pre-treatment QA for Lung SBRT VMAT based on EBT3 film 
inside the body of the Delta4 phantom is feasible. 
Advantages are high spatial resolution and two-plane dose 
information in a cylindrical phantom. Further evaluation 
for more cases and different prescription doses is 
necessary.  
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Purpose or Objective 
The main purpose was to investigate the effects of 
extended computed tomography (ECT) scale and single 
energy metal artifact reduction (SEMAR) algorithm on dose 
distribution during the use of metal implants in 
radiotherapy treatments using 3D-printed individualized 
phantoms. 
Material and Methods 
In this study, measurement was performed for both 
mandible and spinal titanium alloy implants. To evaluate 
the effect of these implants on real treatment case, three 
individualized phantoms were printed using MakerBot 
Replicator Z18 3D printer. In the first case, mandible 
implant was fixed to sawbone mandible model and it was 
placed inside of the individualized phantom. In the second 
and third case, two different spinal implants for C1-C3 and 
C4-C7 vertebra were instrumented to bone equivalent 
sawbone cervical vertebra model and these model were 
placed into the 3D-printed phantoms. CT scans of these 
phantoms were performed in two different step, with and 
without SEMAR methods, using Toshiba Aquilion LB CT 
simulator. In the treatment planning Varian Eclipse 
Version 7.1.3 TPS was used and measurement was 
performed on Varian Clinac DHX High Performance linear 
accelerator In the first case, IMRT plans were created for 
both standard CT Scale ( from -1024 HU to 3071 HU) and 
ECT scale (from -1024 HU to 64.511 HU). In the second and 
third case, in addition to CT scale comparisons for 3D-CRT 
and IMRT techniques, effect of SEMAR methods on dose 
distribution were analyzed for 3D-CRT treatment plans. 
Measurements were performed with EBT3 gafchromic film 
and 5mm DTA/%5 DD criteria was used for gamma analysis 
criteria. 
Results 
In the first case, significant difference was not observed 
for SEMAR +/-, ECTS +/- since the implant used in the 
mandible phantom was thin and small so that it did not 
create dominant artifacts in the CT image. However, in 
C1-C3 and C4-C7 scenarios, it was observed that the ECT 
scale results were generally better (2-16% better) than 
SCT scale. When analyzing the gamma analysis data 
obtained for the planning of vertebral phantoms, no 
significant difference could be obtained from SEMAR +/- 
conditions. 
Conclusion 
in case of significant metal artefact, use of ECT scale can 
improve the dosimetric accuracy of treatment planning. 
However, in mandible implant  dosimetrical differences 
were not found, since thin and small implants were 
prefferd in clinical use. 
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Purpose or Objective 
To ensure safe dose delivery in radiotherapy, 
uncertainties and errors have to be minimized by an 
extended quality assurance (QA) protocol. An established 
part of this chain is pre-treatment verification of monitor 
units, which can be performed by an independent dose re-
calculation. Especially for complex non-isocentric 
treatment plans as delivered by the Cyberknife with multi-
leaf collimator (MLC), the traditional point-based MU 
verification does not suffice and a 3D dose recalculation is 
preferred for plan QA.  The purpose of this work was to 
commission the first commercially available 3D Monte 
